Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation

Inflammatory Bowel Diseases

Volumn 21, Issue 10, 2015, Pages 2441-2452

  Siakavellas, Spyros I ^a   Bamias, Giorgos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

cytokines; DcR3; DR3; inflammatory bowel disease; TL1A

Indexed keywords

CASPASE 3; CD161 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR9; CYTOKINE; DEATH RECEPTOR 3; DECOY RECEPTOR 3; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 22; MITOGEN ACTIVATED PROTEIN KINASE P38; PATTERN RECOGNITION RECEPTOR; STAT1 PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR LIKE CYTOKINE 1A; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; TNFRSF25 PROTEIN, HUMAN; TNFRSF6B PROTEIN, HUMAN; TNFSF15 PROTEIN, HUMAN;

AMPLICON; ANAEROBE; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; BACTEROIDE THETAIOTAOMICRON; BIFIDOBACTERIUM BREVE; CAMPYLOBACTER JEJUNI; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CLOSTRIDIUM; CROHN DISEASE; CROSS LINKING; CYTOKINE RELEASE; DISEASE ASSOCIATION; EFFECTOR CELL; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; IMMUNOPHENOTYPING; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LYMPHOCYTE ACTIVATION; LYMPHOID CELL; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS EPIDERMIDIS; SYNOVIOCYTE; SYSTEMIC CIRCULATION; TH1 CELL; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; ANIMAL; HELPER CELL; HOMEOSTASIS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HOMEOSTASIS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICE; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; UP-REGULATION;

EID: 84942278854     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000492     Document Type: Article

References (100)

1. Migone TS, Zhang J, Luo X, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002; 16:479-492.
2. Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 1997;204:35-46.
3. Zhan C, Yan Q, Patskovsky Y, et al. Biochemical and structural characterization of the human TL1A ectodomain. Biochemistry. 2009;48: 7636-7645.
4. Kitson J, Raven T, Jiang YP, et al. A death-domain-containing receptor that mediates apoptosis. Nature. 1996;384:372-375.
5. Wang EC, Kitson J, Thern A, et al. Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics. 2001;53:59-63.
6. Screaton GR, Xu XN, Olsen AL, et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA. 1997;94:4615-4619.
7. Chinnaiyan AM, O'Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 1996;274:990-992.
8. Gout S, Morin C, Houle F, et al. Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res. 2006;66:9117-9124.
9. Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998; 396:699-703.
10. Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol. 2011;81:838-847.
11. Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHTmediated apoptosis. J Biol Chem. 1999;274:13733-13736.
12. Bamias G, Martin C III, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868-4874.
13. Prehn JL, Mehdizadeh S, Landers CJ, et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol. 2004;112:66-77.
14. Bamias G, Kaltsa G, Siakavellas SI, et al. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Dig Liver Dis. 2012;44:30-36.
15. Bamias G, Kaltsa G, Siakavellas SI, et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol. 2010;137:242-249.
16. Lu Y, Gu X, Chen L, et al. Interferon-gamma produced by tumorinfiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells. Angiogenesis. 2014;17:529-540.
17. Papadakis KA, Zhu D, Prehn JL, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol. 2005;174: 4985-4990.
18. Bamias G, Mishina M, Nyce M, et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA. 2006;103:8441-8446.
19. Prehn JL, Thomas LS, Landers CJ, et al. The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol. 2007;178:4033-4038.
20. Cassatella MA, Pereira-da-Silva G, Tinazzi I, et al. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol. 2007;178:7325-7333.
21. Endo K, Kinouchi Y, Kakuta Y, et al. Involvement of NF-kappa B pathway in TL1A gene expression induced by lipopolysaccharide. Cytokine. 2010;49:215-220.
22. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet. 2005;14:3499-3506.
23. Kakuta Y, Ueki N, Kinouchi Y, et al. TNFSF15 transcripts from risk haplotype for Crohn's disease are overexpressed in stimulated T cells. Hum Mol Genet. 2009;18:1089-1098.
24. Shih DQ, Kwan LY, Chavez V, et al. Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol. 2009;39:3239-3250.
25. Saruta M, Michelsen KS, Thomas LS, et al. TLR8-mediated activation of human monocytes inhibits TL1A expression. Eur J Immunol. 2009;39: 2195-2202.
26. Kamada N, Hisamatsu T, Honda H, et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis. 2010;16:568-575.
27. Bamias G, Evangelou K, Vergou T, et al. Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol. 2011;20:725-731.
28. Zhang J, Wang X, Fahmi H, et al. Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol. 2009;183:5350-5357.
29. Takahashi M, Miura Y, Hayashi S, et al. DcR3-TL1A signalling inhibits cytokine-induced proliferation of rheumatoid synovial fibroblasts. Int J Mol Med. 2011;28:423-427.
30. Papadakis KA, Prehn JL, Landers C, et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol. 2004;172:7002-7007.
31. Cavallini C, Lovato O, Bertolaso A, et al. The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. PLoS One. 2013;8:e60136.
32. Wang X, Hu Y, Charpentier T, et al. TNF-like ligand 1A (TL1A) gene knockout leads to ameliorated collagen-induced arthritis in mice: implication of TL1A in humoral immune responses. J Immunol. 2013;191:5420-5429.
33. Fang L, Adkins B, Deyev V, et al. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med. 2008;205:1037-1048.
34. Wang J, Al-Lamki RS, Zhu X, et al. TL1-A can engage death receptor-3 and activate NF-kappa B in endothelial cells. BMC Nephrol. 2014;15:178.
35. Bu R, Borysenko CW, Li Y, et al. Expression and function of TNFfamily proteins and receptors in human osteoblasts. Bone. 2003;33: 760-770.
36. Fayad R, Brand MI, Stone D, et al. Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. Eur J Immunol. 2006;36:2215-2222.
37. Funke B, Autschbach F, Kim S, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut. 2009;58:483-491.
38. Sessler T, Healy S, Samali A, et al. Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol Ther. 2013;140:186-199.
39. Wen L, Zhuang L, Luo X, et al. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem. 2003;278:39251-39258.
40. Xu LX, Grimaldo S, Qi JW, et al. Death receptor 3 mediates TNFSF15-and TNFalpha-induced endothelial cell apoptosis. Int J Biochem Cell Biol. 2014;55:109-118.
41. Lee SY, Debnath T, Kim SK, et al. Anti-cancer effect and apoptosis induction of cordycepin through DR3 pathway in the human colonic cancer cell HT-29. Food Chem Toxicol. 2013;60:439-447.
42. Bamias G, Jia LG, Cominelli F. The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation. Curr Opin Gastroenterol. 2013;29:597-602.
43. Pappu BP, Borodovsky A, Zheng TS, et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med. 2008;205:1049-1062.
44. Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and Thelper 17 activation. Gastroenterology. 2008;135:552-567.
45. Jones GW, Stumhofer JS, Foster T, et al. Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J. 2011;25:409-419.
46. Zhou M, Liu R, Su D, et al. TL1A increased the differentiation of peripheral Th17 in rheumatoid arthritis. Cytokine. 2014;69:125-130.
47. Jin S, Chin J, Seeber S, et al. TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFalpha, from CD3+CD161+ T cells to exacerbate gut inflammation. Mucosal Immunol. 2013;6:886-899.
48. Cohavy O, Shih DQ, Doherty TM, et al. Cd161 defines effector T cells that express light and respond to Tl1a-Dr3 signaling. Eur J Microbiol Immunol (Bp). 2011;1:70-79.
49. Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gutresident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med. 2009;206:525-534.
50. Meylan F, Song YJ, Fuss I, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011; 4:172-185.
51. Taraban VY, Slebioda TJ, Willoughby JE, et al. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol. 2011;4:186-196.
52. Shih DQ, Barrett R, Zhang X, et al. Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One. 2011;6:e16090.
53. Schreiber TH, Podack ER. Immunobiology of TNFSF15 and TNFRSF25. Immunol Res. 2013;57:3-11.
54. Schreiber TH, Wolf D, Podack ER. The role of TNFRSF25:TNFSF15 in disease... and health? Adv Exp Med Biol. 2011;691:289-298.
55. Schreiber TH, Wolf D, Tsai MS, et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest. 2010;120:3629-3640.
56. Khan SQ, Tsai MS, Schreiber TH, et al. Cloning, expression, and functional characterization of TL1A-Ig. J Immunol. 2013;190:1540-1550.
57. Yu X, Pappu R, Ramirez-Carrozzi V, et al. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol. 2014;7:730-740.
58. Meylan F, Hawley ET, Barron L, et al. The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells. Mucosal Immunol. 2014;7:958-968.
59. Longman RS, Diehl GE, Victorio DA, et al. CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med. 2014;211:1571-1583.
60. Hedl M, Abraham C. A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1. Proc Natl Acad Sci USA. 2014;111:13451-13456.
61. Kakuta Y, Kinouchi Y, Negoro K, et al. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut. 2006;55:1527-1528.
62. Latiano A, Palmieri O, Latiano T, et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One. 2011;6:e22688.
63. Yang SK, Hong M, Zhao W, et al. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut. 2014;63:80-87.
64. Baskaran K, Pugazhendhi S, Ramakrishna BS. Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with Ulcerative Colitis and Crohn's disease in an Indian population. PLoS One. 2014;9:e114665.
65. Tremelling M, Berzuini C, Massey D, et al. Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. Inflamm Bowel Dis. 2008;14:733-737.
66. Wei SC, Ni YH, Yang HI, et al. A hospital-based study of clinical and genetic features of Crohn's disease. J Formos Med Assoc. 2011;110: 600-606.
67. Picornell Y, Mei L, Taylor K, et al. TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis. 2007;13:1333-1338.
68. Zhang J, Wu D, Wang J, et al. Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Autoimmunity. 2014;47:512-518.
69. Cleynen I, Gonzalez JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut. 2013;62: 1556-1565.
70. Yang DH, Yang SK, Song K, et al. TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans. J Crohns Colitis. 2014;8:1315-1326.
71. Tung CC, Wong JM, Lee WC, et al. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease. J Gastroenterol Hepatol. 2014;29:723-729.
72. Hirano A, Yamazaki K, Umeno J, et al. Association study of 71 European Crohn's disease susceptibility loci in a Japanese population. Inflamm Bowel Dis. 2013;19:526-533.
73. Chen H, Lee A, Bowcock A, et al. Influence of Crohn's disease risk alleles and smoking on disease location. Dis Colon Rectum. 2011;54: 1020-1025.
74. Connelly TM, Berg AS, Harris L III, et al. Genetic determinants associated with early age of diagnosis of IBD. Dis Colon Rectum. 2015;58: 321-327.
75. Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16:1830-1840.
76. Michelsen KS, Thomas LS, Taylor KD, et al. IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein. PLoS One. 2009;4:e4719.
77. Spencer DM, Veldman GM, Banerjee S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology. 2002;122:94-105.
78. Bamias G, Martin C, Mishina M, et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology. 2005;128:654-666.
79. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol. 2007;23:365-369.
80. Pizarro TT, Pastorelli L, Bamias G, et al. SAMP1/YitFc mouse strain: a spontaneous model of Crohn's disease-like ileitis. Inflamm Bowel Dis. 2011;17:2566-2584.
81. Tougaard P, Skov S, Pedersen AE, et al. TL1A regulates TCRgammadelta(+) intraepithelial lymphocytes and gut microbial composition. Eur J Immunol. 2015;45:865-875.
82. Wang EC, Thern A, Denzel A, et al. DR3 regulates negative selection during thymocyte development. Mol Cell Biol. 2001;21:3451-3461.
83. Meylan F, Davidson TS, Kahle E, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity. 2008;29:79-89.
84. Lawrance IC, Rogler G, Bamias G, et al. Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis. [published online ahead of print October 8, 2014]. doi: 10.1016/j.crohns.2014.09.008.
85. Latella G, Rogler G, Bamias G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. 2014;8:1147-1165.
86. Zheng L, Zhang X, Chen J, et al. Sustained Tl1a expression on both lymphoid and myeloid cells leads to mild spontaneous intestinal inflammation and fibrosis. Eur J Microbiol Immunol (Bp). 2013;3:11-20.
87. Barrett R, Zhang X, Koon HW, et al. Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am J Pathol. 2012;180: 636-649.
88. Shih DQ, Zheng L, Zhang X, et al. Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis. Mucosal Immunol. 2014;7: 1492-1503.
89. Hayashi S, Miura Y, Nishiyama T, et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum. 2007;56:1067-1075.
90. Bamias G, Siakavellas SI, Stamatelopoulos KS, et al. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin Immunol. 2008;129:249-255.
91. Konsta M, Bamias G, Tektonidou MG, et al. Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. Rheumatology (Oxford). 2013;52:448-451.
92. Wang EC, Newton Z, Hayward OA, et al. Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis Rheumatol. 2014;66:2762-2772.
93. Zinovieva E, Bourgain C, Kadi A, et al. Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. PLoS Genet. 2009;5: e1000528.
94. Kepiro L, Szell M, Kovacs L, et al. Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritis. Hum Immunol. 2014; 75:159-162.
95. Calder CJ, Wang EC. An essential role for death receptor 3 in experimental autoimmune uveoretinitis. Ocul Immunol Inflamm. 2012;20: 212-214.
96. Bamias G, Stamatelopoulos K, Zampeli E, et al. Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. Clin Immunol. 2013;147: 144-150.
97. Sachdev AH, Pimentel M. Identifying and testing candidate genetic polymorphisms in irritable bowel syndrome: association with TNFSF15 and tumor necrosis factor-alpha. Ann Gastroenterol. 2013;26:87-88.
98. Camilleri M, Carlson P, Acosta A, et al. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol. 2014;306:G1089-G1098.
99. Connelly TM, Berg AS, Hegarty JP, et al. The TNFSF15 gene single nucleotide polymorphism rs7848647 is associated with surgical diverticulitis. Ann Surg. 2014;259:1132-1137.
100. Sehgal R, Berg A, Polinski JI, et al. Genetic risk profiling and gene signature modeling to predict risk of complications after IPAA. Dis Colon Rectum. 2012;55:239-248.